1291 related articles for article (PubMed ID: 29540348)
1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Hallek M; Cheson BD; Catovsky D; Caligaris-Cappio F; Dighiero G; Döhner H; Hillmen P; Keating M; Montserrat E; Chiorazzi N; Stilgenbauer S; Rai KR; Byrd JC; Eichhorst B; O'Brien S; Robak T; Seymour JF; Kipps TJ
Blood; 2018 Jun; 131(25):2745-2760. PubMed ID: 29540348
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Döhner H; Estey E; Grimwade D; Amadori S; Appelbaum FR; Büchner T; Dombret H; Ebert BL; Fenaux P; Larson RA; Levine RL; Lo-Coco F; Naoe T; Niederwieser D; Ossenkoppele GJ; Sanz M; Sierra J; Tallman MS; Tien HF; Wei AH; Löwenberg B; Bloomfield CD
Blood; 2017 Jan; 129(4):424-447. PubMed ID: 27895058
[TBL] [Abstract][Full Text] [Related]
3. Is MRD eradication a desirable goal in CLL?
Moreno C; Ritgen M; Rawstron A
Best Pract Res Clin Haematol; 2010 Mar; 23(1):97-107. PubMed ID: 20620974
[TBL] [Abstract][Full Text] [Related]
4. SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia.
Choi MY; Wang HY; Kipps TJ
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):321-325. PubMed ID: 31204237
[TBL] [Abstract][Full Text] [Related]
5. The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
Cheson BD; Mato AR
Clin Adv Hematol Oncol; 2020 Jun; 18 Suppl 10(6):1-20. PubMed ID: 33843867
[TBL] [Abstract][Full Text] [Related]
6. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O'Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E; Ghia P
Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
Hallek M; Cheson BD; Catovsky D; Caligaris-Cappio F; Dighiero G; Döhner H; Hillmen P; Keating MJ; Montserrat E; Rai KR; Kipps TJ;
Blood; 2008 Jun; 111(12):5446-56. PubMed ID: 18216293
[TBL] [Abstract][Full Text] [Related]
8. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
[TBL] [Abstract][Full Text] [Related]
9. Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines.
Molica S; Giannarelli D; Mirabelli R; Levato L; Gentile M; Lentini M; Morabito F
Expert Rev Hematol; 2014 Oct; 7(5):691-5. PubMed ID: 25174547
[TBL] [Abstract][Full Text] [Related]
10. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples.
Bento L; Correia R; de Sousa F; Vaz A; Pedro E; Schimidell D; Millan N; Passaro M; Barroso R; Bacal N
Cytometry B Clin Cytom; 2020 Nov; 98(6):529-535. PubMed ID: 32251553
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of Chronic Lymphocytic Leukemia Using iwCLL 2018 Compared with NCI-WG96 Criteria in Cipto Mangunkusumo Hospital: A Practical Consideration in Resource Limited Setting.
Sukrisman L; Rinaldi I
Acta Med Indones; 2022 Oct; 54(4):531-539. PubMed ID: 36624709
[TBL] [Abstract][Full Text] [Related]
12. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C
Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580
[TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL).
Magnac C; Sutton L; Cazin B; Laurent C; Binet JL; Merle-Béral H; Dighiero G; Maloum K
Hematol Cell Ther; 1999 Feb; 41(1):13-8. PubMed ID: 10193641
[TBL] [Abstract][Full Text] [Related]
14. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease assessment in chronic lymphocytic leukaemia.
Sayala HA; Rawstron AC; Hillmen P
Best Pract Res Clin Haematol; 2007 Sep; 20(3):499-512. PubMed ID: 17707836
[TBL] [Abstract][Full Text] [Related]
16. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL).
Eichhorst B; Hallek M
Best Pract Res Clin Haematol; 2007 Sep; 20(3):469-77. PubMed ID: 17707834
[TBL] [Abstract][Full Text] [Related]
17. CLL response criteria.
Cheson BD
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 10; suppl 12. PubMed ID: 16830419
[No Abstract] [Full Text] [Related]
18. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.
Molica S; Giannarelli D; Montserrat E
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):423-430. PubMed ID: 31027992
[TBL] [Abstract][Full Text] [Related]
19. MRD in CLL.
Hillmen P
Clin Adv Hematol Oncol; 2006 May; 4(5):6-7; discussion 10; suppl 12. PubMed ID: 16830420
[No Abstract] [Full Text] [Related]
20. Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.
Farren TW; Giustiniani J; Fanous M; Liu F; Macey MG; Wright F; Prentice A; Nathwani A; Agrawal SG
Blood Cancer J; 2015 Jan; 5(1):e273. PubMed ID: 25615279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
